Polymorphisms of TP53 codon 72 with breast carcinoma risk: evidence from 12226 cases and 10782 controls

Table 1 Characteristics of studies included in the meta-analysis

First Author	Publication Year	Number of Cases	Number of Controls	Types of Cases	Type of controls	Method	Country	Ref. No.
Själander	1996	212	689	Ductal carcinoma (>80% of the total cases)	Pooled individuals from several controls	PCR-RFLP	Sweden	43
Weston	1997	81	147	NS	NS	AS-PCR	USA	44
Li	2002	28	50	NS	50 healthy people (age-matched)	AS-PCR	China	45
Wang-Gohrke	2002	577	579	NS	NS	PCR-RFLP	Germany	46
Buyru	2003	115	76	NS	76 healthy people	PCR-RFLP	Turkey	47
Huang	2003	200	282	NS	282 healthy people	PCR-CTPP	China	48
Katiyar	2003	77	41	77 Sporadic breast cancer	41 Normal healthy women (age-matched)	PCR-RFLP	India	49
Mabrouk	2003	30	49	NS	NS	PCR-RFLP	Tunisia	50
Kalemi	2005	42	51	NS	51 healthy women	PCR-RFLP	UK	51
Tommiska	2005	1827	736	888 unselected breast cancer; 939 familial breast cancer	736 healthy population	TaqMan	Sweden	52
Baynes	2007	2023	2197	NS	NS	TaqMan	UK	53
Gochhait	2007	576	243	243 sporadic breast cancer; 333 unrelated breast cancer	243 healthy females (ethnically and geographically matched)	PCR-RFLP	India	54
Khadang	2007	221	205	221 sporadic breast cancer	205 healthy blood donors	AS-PCR	Iran	55
Schmidt	2007	5191	3834	NS	NS	TaqMan+ PCR-RFLP	UK	56
Sprague	2007	1912	1527	1708 invasive breast cancer; 204 in situ breast cancer	1527 drivers (< 65 year) and roster of Medicare beneficiaries (65–74 year)	TaqMan	USA	57
Zhang	2007	84	168	NS	168 healthy controls (geographic- and age-matched)	PCR-RFLP	China	59
Akkiprik	2008	95	107	NS	107 age-matched healthy controls	PCR-RFLP	Turkey	58

AS-PCR: Allele Specific PCR; RFLP: restriction fragment length polymorphism; CTPP: confronting two-pair primers; NS: not specified

ISSN: 1756-9966